The Ministry of Health of the Russian Federation issued a registration certificate to the Russian company AxelPharm for the drug Ruxolitinib, a generic version of Jakavi from the Swiss Novartis. The drug is intended for the treatment of myelofibrosis and the prevention of graft-versus-host disease.
The drug will be produced by OncoTarget. The worldwide patent protection for ruxolitinib will remain in force until 2028. Myelofibrosis is a rare blood cancer where scar tissue forms in your bone marrow. It’s a form of chronic leukemia.
